Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Zyprexa ® (olanzapine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Zyprexa® (olanzapine): Breaking or Dividing Tablets
Zyprexa coated tablets are not scored and not intended to be broken or divided. The package leaflet recommends swallowing the tablets whole with water.
cFAQ
cFAQ
UK_cFAQ_OLZ240_BREAKING_DIVING_TABLETS
en-GB
Additional Safety Information
Confirmed cases of allergic contact dermatitis have been reported with olanzapine. Symptoms have included rash with redness, swelling, and scaling of the affected skin areas. Positive reactions have been verified by patch testing with olanzapine (0.1%). Based on the clinical dose, olanzapine is highly potent.1
Likewise, olanzapine may be irritating to the eyes based on animal studies. Care should be exercised not to inadvertently transfer material from the hands to the eye.2
Additional safety information about olanzapine can be found in the full prescribing information and in the material safety data sheet for olanzapine, available upon request from Eli Lilly and Company.
References
1Olanzapine [materials safety data sheet]. Eli Lilly and Company: Indianapolis, IN, August 11, 2015. http://ehs.lilly.com/msds/Zyprexa%20(tablets).pdf . Accessed October 10, 2019.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: 10 October 2019
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays